Professor Jacob George
People_

Professor Jacob George

MBBS, FRACP, PhD, FAASLD
Robert W Storr Chair of Hepatic Medicine, Sydney Medical School
Director, Storr Liver Centre, The Westmead Institute for Medical Research
Head, Department of Gastroenterology &
Hepatology, Westmead Hospital and Sydney West Local Health District
Phone
+61 2 9845 7705
Fax
+61 2 9635 7582
Professor Jacob George

Professor Jacob George is a renowned hepatologist and liver research scientist who studies the causes of and mechanisms for the development of liver disease and liver cancer. He contributes to investigator-initiated and multicentre international clinical trials on therapeutics for liver diseases, and leads a program of research on viral hepatitis, fatty liver disease, liver fibrosis, host genetics/liver immunology and the epidemiology, prevention and management of liver cancer. His research has a strong translational component, linking laboratory and clinical research. Professor George’s work has made significant contributions to clinical practice. His team first identified the role of interferon lambda 3 gene polymorphisms for predicting treatment response in chronic hepatitis C, and a second gene polymorphism that interacts with interferon lambda 3. These discoveries are considered major advances in the field and the finest examples of ‘personalised medicine’. Professor George was an author on the groundbreaking study of combination telaprevir, pegylated interferon and ribavirin therapy for hepatitis C, which changed the landscape of hepatitis C treatments, heralding the era of direct-acting antivirals. His work identifying insulin resistance as the universal underlying pathophysiological abnormality in fatty liver disease underpins the majority of research on this condition and is the cornerstone of current therapy (lifestyle intervention; exercise; insulin-sensitising agents). He also first described the association between hepatitis C and insulin resistance. Professor George is an advisor to Hepatitis Australia, the Transfusion Related AIDS and Infectious Diseases Service, and at state and national levels, on viral hepatitis. He oversees research for the Asian Pacific Association for the Study of Liver. He is a Fellow of the American Association for the Study of Liver Disease.

Professor George’s research broadly covers liver disease and cancer, with specific themes in the fields of viral hepatitis, liver cancer, fatty liver disease, hepatic drug metabolism, and the contribution of host genetics and immunology to liver disease, liver injury and fibrosis. He has particular interests in basic and clinical research on non-alcoholic steatohepatitis and on the role of host genetics in treatment response and disease progression in viral hepatitis.

Professor George leads an international genetics hepatitis C consortium that includes 4,200 patients from Australia, Egypt, Germany, Italy, the UK, Hong Kong, etc. The consortium provides the opportunity to access patients with distinct genetic backgrounds to help identify host factors that are associated with treatment response and/or the development of liver fibrosis and disease progression. His team is attempting to develop diagnostic tests to non-invasively predict liver fibrosis stage, thereby avoiding liver biopsies. Additionally, with the aid of a major grant from the Cancer Council of NSW and the Cancer Institute, NSW, Professor George is undertaking a program of research investigating the epidemiology, pathogenesis and treatment of liver cancer, a malignancy that is rapidly increasing in incidence in NSW. The aim of the work is to develop new preventative and early detection strategies and treatments.

Cancer, Infection and Immunological Conditions, Healthy Ageing
Project titleResearch student
Screening Approaches for Non-Cirrhotic MAFLD Patients at the Risk of Developing HCC: An Early InterventionFatema SAFRI
Exploring the potential of ctDNA and the Notch Signalling Pathway as biomarkers for the early detection of Hepatocellular Carcinoma (HCC)William YANG

Selected publications

Publications

Edited Books

  • Qiao, L., Li, Y., Yan, X., George, J. (2012). Molecular Aspects of Hepatocellular Carcinoma. Sharjah: Bentham Science Publishers.

Book Chapters

  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]
  • Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing. [More Information]
  • Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 813-832). London: Imperial College Press. [More Information]

Journals

  • Pan, Z., Alharthi, J., Bayoumi, A., George, J., Eslam, M. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience - Landmark, 29(4), 148. [More Information]
  • Zhang, H., Crespo, J., Grønbæk, H., Yang, W., Eslam, M., Wong, R., Machado, M., Yu, M., Ghanem, O., Okanoue, T., George, J., et al (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International. [More Information]
  • Feng, G., Schattenberg, J., Labenz, C., Mahadeva, S., Chan, W., Chi, X., Delamarre, A., De Ledinghen, V., Petta, S., Bugianesi, E., George, J., et al (2024). acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. Clinical Gastroenterology and Hepatology. [More Information]

Conferences

  • Parker, H., O'Connor, H., Cohn, J., Garg, M., Johnson, N., Caterson, I., George, J. (2015). Effect of combined fish oil plus coenzyme Q10 supplementation on Omega-3 Index and cardiovascular risk markers in overweight men. Joint Annual Scientific Meeting of the Nutrition Society of New Zealand and the Nutrition Society of Australia, New Zealand: Nutrition Society of Australia and Nutrition Society of New Zealand.
  • Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Efficacy of the Omega-3 Index in predicting NAFLD in overweight and obese adults: a pilot study. 2014 Australian and New Zealand Obesity Society Annual Scientific Meeting, Sydney, Australia: Australian and New Zealand Obesity Society.
  • Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Omega-3 Index and liver fat: an unexpected relationship. Nutrition Society of Australia 2014 Annual Scientific Meeting, Australia.

Patents

  • Booth, D., Ahlenstiel, G., George, J., O'Connor, K., Eslam, M. (2021). A method to predict rate of fibrosis in liver diseases. Patent No. 10,939,868.

Magazine / Newspaper Articles

  • Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.

2024

  • Pan, Z., Alharthi, J., Bayoumi, A., George, J., Eslam, M. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience - Landmark, 29(4), 148. [More Information]
  • Zhang, H., Crespo, J., Grønbæk, H., Yang, W., Eslam, M., Wong, R., Machado, M., Yu, M., Ghanem, O., Okanoue, T., George, J., et al (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International. [More Information]
  • Feng, G., Schattenberg, J., Labenz, C., Mahadeva, S., Chan, W., Chi, X., Delamarre, A., De Ledinghen, V., Petta, S., Bugianesi, E., George, J., et al (2024). acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. Clinical Gastroenterology and Hepatology. [More Information]

2023

  • Kalo, E., Baig, A., Gregg, E., George, J., Read, S., Ma, W., Ahlenstiel, G. (2023). A novel, nurse-led ‘one stop’ clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. BMC Gastroenterology, 23(1). [More Information]
  • Fischer, J., Long, S., Koukoulioti, E., Müller, T., Fueloep, B., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., et al (2023). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens, 12(1). [More Information]
  • Ramírez-Mejía, M., Jiménez-Gutiérrez, C., Eslam, M., George, J., Méndez-Sánchez, N. (2023). Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification? Hepatology International. [More Information]

2022

  • Younossi, Z., Ong, J., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M., Fan, J., George, J., et al (2022). A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 20(6), e1456-e1468. [More Information]
  • Alharthi, J., Bayoumi, A., Thabet, K., Pan, Z., Gloss, B., Latchoumanin, O., Lundberg, M., Twine, N., McLeod, D., Alenizi, S., Liddle, C., George, J., Eslam, M., et al (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications, 13(1). [More Information]
  • Lazarus, J., Anstee, Q., Arab, J., Batterham, R., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M., Francque, S., George, J., et al (2022). Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews. Gastroenterology & Hepatology, 19(1), 60-78. [More Information]

2021

  • Eslam, M., Wong, G., Hashem, A., Chan, H., Nielsen, M., Leeming, D., Chan, A., Chen, Y., Duffin, K., Karsdal, M., George, J., et al (2021). A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 116(5), 984-993. [More Information]
  • Calzadilla-Bertot, L., Vilar-Gomez, E., Wong, V., Romero-Gomez, M., Aller-de la Fuente, R., Wong, G., Castellanos, M., Eslam, M., Desai, A., Jeffrey, G., George, J., et al (2021). ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology, 73(6), 2238-2250. [More Information]
  • Lockart, I., Hajarizadeh, B., Buckley, N., Davison, S., Prakoso, E., Levy, M., George, J., Dore, G., Danta, M. (2021). All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. Journal of Gastroenterology and Hepatology, 36(12), 3515-3523. [More Information]

2020

  • Eslam, M., Newsome, P., Sarin, S., Anstee, Q., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J., Schattenberg, J., George, J., et al (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209. [More Information]
  • Tu, T., Zehnder, B., Qu, B., Ni, Y., Main, N., Allweiss, L., Dandri, M., Shackel, N., George, J., Urban, S. (2020). A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Research, 181, 104865. [More Information]
  • George, J., Rappaport, M., Shimoni, S., Goland, S., Voldarsky, I., Fabricant, Y., Edri, O., Cuciuc, V., Lifshitz, S., Tshori, S., et al (2020). A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. European Heart Journal, 41(12), 1260-1270. [More Information]

2019

  • Li, G., Chan, Y., Sukjamnong, S., Anwer, A., Vindin, H., Padula, M., Zakarya, R., George, J., Oliver, B., Saad, S., et al (2019). A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients, 11(7), 1-14. [More Information]
  • Metwally, M., Bayoumi, A., Romero-Gomez, M., Thabet, K., John, M., Adams, L., Huo, X., Aller, R., Garcia-Monzon, C., Arias-Loste, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3 ' UTR. Journal of Hepatology, 70(3), 494-500. [More Information]
  • El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 9(1), 1-10. [More Information]

2018

  • Kawaguchi, T., Tokushige, K., Hyogo, H., Aikata, H., Nakajima, T., Ono, M., Kawanaka, M., Sawada, K., Imajo, K., Honda, K., George, J., et al (2018). A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Scientific Reports, 8(1), 1-13. [More Information]
  • Kabir, T., Ganda, C., Brown, R., Beveridge, D., Richardson, K., Chaturvedi, V., Candy, P., Epis, M., Wintle, L., Kalinowski, F., George, J., et al (2018). A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology, 67(1), 216-231. [More Information]
  • El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Douglas, M., Khan, A., et al (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 564-573. [More Information]

2017

  • Siddiqui, M., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., Abelega, N., Carr, D., Bloch, K., Hallberg, P., et al (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 38(48), 3569-3575. [More Information]
  • Gauthiez, E., Habfast-Robertson, I., Rueger, S., Kutalik, Z., Aubert, V., Berg, T., Cerny, A., Gorgievski, M., George, J., Heim, M., et al (2017). A systematic review and meta-analysis of HCV clearance. Liver International, 37(10), 1431-1445. [More Information]
  • Baatarkhuu, O., Lee, H., George, J., Munkh-Orshikh, D., Enkhtuvshin, B., Ariunaa, S., Eslam, M., Ahn, S., Han, K., Kim, D. (2017). Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. Clinical and Molecular Hepatology, 23(2), 147-153. [More Information]

2016

  • Orriss, I., Arnett, T., George, J., Witham, M. (2016). Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation. Experimental Cell Research, 342(2), 166-174. [More Information]
  • Goland, S., Weinstein, J., Zalik, A., Kuperstein, R., Zilberman, L., Shimoni, S., Arad, M., Ben Gal, T., George, J. (2016). Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. Circulation. Heart Failure, 9(11). [More Information]
  • Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2016). Aptamers: A promising chemical antibody for cancer therapy. Oncotarget, 7(12), 13446-13463. [More Information]

2015

  • Dong, Z., Su, L., Esmaili, S., Iseli, T., Ramezani-Moghadam, M., Hu, L., Xu, A., George, J., Wang, J. (2015). Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. Journal of Molecular Medicine, 93(12), 1327-1339. [More Information]
  • Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T., Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 290(9), 5533-5542. [More Information]
  • Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 29(8), 1240-1247. [More Information]

2014

  • Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-alpha in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
  • Muir, A., Arora, S., Everson, G., Flisiak, R., George, J., Ghalib, R., Gordon, S., Gray, T., Greenbloom, S., Hassanein, T., et al (2014). A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 61(6), 1238-1246. [More Information]
  • Bhide, R., Barman, A., Varghese, S., Chatterjee, A., Mammen, S., George, J., Thomas, R. (2014). A rare presentation of subacute progressive ascending myelopathy secondary to cement leakage in percutaneous vertebroplasty. American Journal of Physical Medicine & Rehabilitation, 93(5), 431-436. [More Information]

2013

  • Nair, S., George, J., Kumar, S., Gracious, N., Das, M. (2013). A case of Goodpasture's syndrome complicating pregnancy with dialysis requiring renal failure responding to plasmapheresis and termination of pregnancy. Renal Failure, 35(8), 1173-1175. [More Information]
  • Szwejkowski, B., Gandy, S., Rekhraj, S., Houston, J., Lang, C., Morris, A., George, J., Struthers, A. (2013). Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. Journal of the American College of Cardiology, 62(24), 2284-2293. [More Information]
  • Beveridge, L., Ramage, L., Mcmurdo, M., George, J., Witham, M. (2013). Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age and Ageing, 42(3), 400-404. [More Information]

2012

  • Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. Liver International, 32(6), 988-988. [More Information]
  • Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]

2011

  • Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
  • Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
  • Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 26(10), 1536-1543. [More Information]

2010

  • Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. SportEx Health, 25, 18-20.
  • Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
  • Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. Hepatology, 52(1), 370-381. [More Information]

2009

  • Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49(6), 1926-1934. [More Information]
  • Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology, 49(5), 1765-1767. [More Information]
  • Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 50(4), 1105-1112. [More Information]

2008

  • Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis, 15(10), 753-760. [More Information]
  • van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clinics in Liver Disease, 12(4), 805-824. [More Information]
  • St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology, 24(3), 399-407. [More Information]

2007

  • van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. Journal of Gastroenterology and Hepatology, 22(Supplement 3), A344-A344.
  • Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.
  • Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. Gastroenterology, 133(4), 1377-1378.

2006

  • George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. Journal of Hepatology, 44(4), 832-834. [More Information]
  • Bugianesi, E., Marchesini, G., Gentilcore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 44(6), 1648-1655. [More Information]
  • Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. Journal Of Clinical Virology, 36(Supplement 2), S134-S135.

2005

  • Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. Journal Of Clinical Virology, 32(2), 137-143. [More Information]
  • Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 25(3), 518-526. [More Information]
  • Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5(1), 1-13. [More Information]

2004

  • Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? Hepatology, 40(1), 46-54. [More Information]
  • Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644. [More Information]
  • McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. Gut, 53(3), 318-321. [More Information]

2003

  • Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Molecular Biology of the Cell, 14(6), 2327-2341. [More Information]
  • Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390. [More Information]
  • Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.

2002

  • Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009. [More Information]
  • Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.
  • Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. Medicine Today, 3(10), 58-67.

2001

  • Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive devise user. Postgraduate Medical Journal, 77, 602-610.
  • Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
  • Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.

Selected Grants

2022

  • Building active surveillance systems to track hepatitis C virusepidemiology and antiviral resistance, Douglas M, Kok J, Eden J, Tu T, Cunningham A, George J, Australian Centre for HIV and Hepatitis Virology Research (ACH2)/Research Support
  • A flagship lightsheet, confocal and live cell 4D microscope to turbocharge translational cancer research at the Westmead Health Precinct, George J, Graham J, Robinson P, O'Neill G, Hau E, Fernandez Penas P, Gottlieb D, Ahern V, Cesare A, Schlegel P, Cancer Institute NSW/Equipment Grant

2021

  • Oncofetal ecosystem in advanced Hepatocellular Carcinoma: Implications for Identifying Immunotherapy response, Sharma A, Wallace M, Lucas M, Ginhoux F, Chow P, Yeoh G, Gunawardena D, George J, National Health and Medical Research Council (NHMRC)/Ideas Grant
  • Reducing liver cancer burden, George J, Cancer Council NSW/Sally Crossing AM Award
  • The APRICA program- Accelerated translational research in PRImary Liver Cancer, George J, McCaughan G, Reddel R, Bertolino P, Palendira M, Eslam M, Usherwood T, Cancer Institute NSW/Accelerated Translational Research Grant
  • The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in the Development of Hyperglycaemia in Pregnancy, Cheung N, George J, Pasupathy D, Diabetes Australia Research Trust (DART)/Diabetes Research Grant Program

Related research articles

next slide
previous slide